Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone

S. Bajusz, T. Janaky, V. J. Csernus, L. Bokser, M. Fekete, G. Srkalovic, T. W. Redding, Andrew V Schally

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N(ε)-(DL-2,3-diaminopropionyl)-D-lysine residue (D-Lys-DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1,D-Phe(pCl)2,D-Pal(3)2,Arg5-D-Lys{DL- A2pr(Sal2Cu)}6,D-la10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(DL-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 μg in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides.

Original languageEnglish
Pages (from-to)6313-6317
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume86
Issue number16
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Cisplatin
Lysine
Prostatic Neoplasms
Ovulation Inhibition
Breast Neoplasms
LHRH Receptors
Coordination Complexes
Cytostatic Agents
Platinum
Human Activities
Copper
Hormones
Cell Line
Peptides
Membranes
Neoplasms

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. / Bajusz, S.; Janaky, T.; Csernus, V. J.; Bokser, L.; Fekete, M.; Srkalovic, G.; Redding, T. W.; Schally, Andrew V.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, No. 16, 01.01.1989, p. 6313-6317.

Research output: Contribution to journalArticle

Bajusz, S, Janaky, T, Csernus, VJ, Bokser, L, Fekete, M, Srkalovic, G, Redding, TW & Schally, AV 1989, 'Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone', Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 16, pp. 6313-6317.
Bajusz, S. ; Janaky, T. ; Csernus, V. J. ; Bokser, L. ; Fekete, M. ; Srkalovic, G. ; Redding, T. W. ; Schally, Andrew V. / Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. In: Proceedings of the National Academy of Sciences of the United States of America. 1989 ; Vol. 86, No. 16. pp. 6313-6317.
@article{64f0ff671c234db8b2d169c2c1423529,
title = "Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone",
abstract = "Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N(ε)-(DL-2,3-diaminopropionyl)-D-lysine residue (D-Lys-DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1,D-Phe(pCl)2,D-Pal(3)2,Arg5-D-Lys{DL- A2pr(Sal2Cu)}6,D-la10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(DL-A2pr)6, caused 100{\%} inhibition of ovulation at a dose of 3 μg in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides.",
author = "S. Bajusz and T. Janaky and Csernus, {V. J.} and L. Bokser and M. Fekete and G. Srkalovic and Redding, {T. W.} and Schally, {Andrew V}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "86",
pages = "6313--6317",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "16",

}

TY - JOUR

T1 - Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone

AU - Bajusz, S.

AU - Janaky, T.

AU - Csernus, V. J.

AU - Bokser, L.

AU - Fekete, M.

AU - Srkalovic, G.

AU - Redding, T. W.

AU - Schally, Andrew V

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N(ε)-(DL-2,3-diaminopropionyl)-D-lysine residue (D-Lys-DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1,D-Phe(pCl)2,D-Pal(3)2,Arg5-D-Lys{DL- A2pr(Sal2Cu)}6,D-la10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(DL-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 μg in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides.

AB - Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N(ε)-(DL-2,3-diaminopropionyl)-D-lysine residue (D-Lys-DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1,D-Phe(pCl)2,D-Pal(3)2,Arg5-D-Lys{DL- A2pr(Sal2Cu)}6,D-la10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(DL-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 μg in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides.

UR - http://www.scopus.com/inward/record.url?scp=0004608376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0004608376&partnerID=8YFLogxK

M3 - Article

C2 - 2548206

AN - SCOPUS:0004608376

VL - 86

SP - 6313

EP - 6317

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 16

ER -